

Biosimilars Medicines Group "The Facts about Biosimilars"

EAHP conference - satellite symposium Vienna, 17 March 2016





patients • quality • value • sustainability • partnership



About us

- Medicines for Europe (formerly EGA) is the voice of the pharmaceutical companies supplying the largest share of medicines across Europe and a leading partner for better healthcare for all European patients and healthcare community, representing the generic, biosimilar and value added medicines industries.
- Over 350 manufacturing and research & development sites across Europe produce your essential medicines, employ over 160.000 people and invest up to 17% of their turnover into R&D activities.
- Medicines for Europe members portfolio covers 80% of therapy areas and supplies the majority of all prescribed medicines in Europe.

patients • quality • value • sustainability • partnership



patients • quality • value • sustainability • partnership

Generic Medicines Group



- The Generic Medicines Group is a sector group of *Medicines for Europe*, representing the generic medicines developers and manufacturers across Europe, which provide high-quality costcompetitive medicines to millions of patients around the world.
- The generic medicines industry has increased access to medicines by over 100% in 7 key therapeutic areas without increasing the overall treatment cost.
- Over 350 manufacturing and research & development sites across Europe produce your essential medicines, employ over 160.000 people and invest up to 17% of their turnover into R&D activities.
- Generic medicines account today for 56% of all dispensed medicines but for only 22% of the pharmaceutical expenditure in Europe. In other words, generic medicines only account for 2-4% of total healthcare costs. Without generic medicines, Europe would have had to pay €100 billion more in 2014 to get the same level of access to treatment as we have today.

patients • quality • value • sustainability • partnership

Biosimilar Medicines Group



- The Biosimilar Medicines Group is a sector group of *Medicines for Europe* and represents the leading companies developing, manufacturing and marketing biosimilar medicines across Europe.
- With more than 10 years of positive patient treatment experience and 20 products successfully launched, biosimilar medicines provide today a huge opportunity to deliver significantly improved access to modern therapies for millions of European patients in both chronic and acute care.
- Our members bring competition to the biological medicines market, thereby increasing access to highly innovative medical treatments to patients, in Europe and around the world, and supporting the sustainability of the European healthcare systems.

patients • quality • value • sustainability • partnership



C medicines

Value Added Medicines Group



- The Value Added Medicines Group is a sector group of *Medicines for Europe* which aims at optimising, rethinking and reinventing medicines based on known molecules and by bringing untapped innovation to improve care delivery.
- The Value Added Medicines Group adopts a complementary perspective compared to the other *Medicines for Europe* sector groups: by tackling the targeted portion of patients' needs that remain unmet to this day, delivering additional improvement to the healthcare community as a whole.
- The Value Added Medicines Group brings innovative healthcare while preserving healthcare systems sustainability and access.
- The Value Added Medicines Group will be hosting its first official event next May 31 in Brussels, details will be available soon.

patients • quality • value • sustainability • partnership

C medicines

